Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 113

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 6
Chunk 113
---
X Listing Rule 4.10.3, companies are required to attach a copy of the Company’s
corporate governance statement (which has been approved by the Board) and provide a statement in their annual report to shareholders disclosing
the extent to which they have followed the Recommendations in the reporting period and where they have not followed all the Recommendations,
identify the Recommendations that have not been followed, and the reasons for not following them and what (if any) alternative governance
practices it adopted in lieu of the recommendations during that period. It is not mandatory to follow the Recommendations. We believe
we are in material compliance with the Recommendations except where otherwise stated in our periodic disclosures on ASX.

Non-Executive and Independent Directors

Australian law does not require
a company to appoint a certain number of independent directors to its board of directors or audit committee. However, under the Corporate
Governance Principles and Recommendations, the ASX recommends, but does not require, that an ASX-listed company have a majority of independent
directors on its board of directors. Our Board of Directors has determined that each of Ian Turner, Hester Larkin, Noel Donnelly and Leila
Alland qualifies as an independent director under the requirements of the ASX.

Our Board of Directors does
not have regularly scheduled meetings at which only independent directors are present. The Board of Directors meets regularly and independent
directors are expected to attend all such meetings.

Audit Committee.

Our Audit Committee assists
our Board of Directors in overseeing the accounting and financial reporting processes of our company and audits of our financial statements,
including the integrity of our financial statements, compliance with legal and regulatory requirements, our independent public accountants’
qualifications and independence, and independent public accountants, and such other duties as may be directed by our Board of Directors.
The Audit Committee is also required to assess risk management.

Our Audit Committee consists
of three board members: Ian Turner, Hester Larkin and Noel Donnelly. Noel Donnelly is the Chairman of the Audit Committee. The audit committee
meets at least two times per year.

Nasdaq Marketplace Rules
require us to establish an audit committee comprised of at least three members, each of whom is financially literate and satisfies
the respective “independence” requirements of the SEC and Nasdaq and one of whom has accounting or related financial
management expertise at senior levels within a company. Our board of directors has determined that Noel Donnelly is a
“financial expert” for purpose of these rules. In